Tuesday May 8 | MediLexicon
Study Examines Necessity Of Additional Imaging In PET/CT Oncologic Reports
Radiologists and nuclear medicine physicians recommended additional imaging about 30% of the time in oncologic PET/CT reports, with about half of those recommendations being unnecessary, a new study shows.
Onyx Pharmaceuticals, Inc. Says FDA's ODAC Will Review NDA For Carfilzomib
SOUTH SAN FRANCISCO, April 26, 2012 /PRNewswire via COMTEX/ -- Onyx Pharmaceuticals, Inc.
Tekmira Provides Update on Licensed Product Candidate, Marqibo
Vancouver, BC March 21, 2012 - Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, disclosed that its licensing partner, Talon Therapeutics, Inc., announced today that the Oncologic Drugs Advisory Committee voted 7 yes, 4 no, and 2 abstain that evidence from clinical studies supports a favorable benefit/risk ... (more)
Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch
In a February 27, 2012 article I gave a small list of bio-pharma companies with their drugs that were facing FDA decisions for approval or rejection.
Also on Topix